Department of Health Data Science, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.
Clin Trials. 2024 Aug;21(4):470-482. doi: 10.1177/17407745241230287. Epub 2024 Mar 14.
BACKGROUND/AIMS: Information regarding the use of wearable devices in clinical research, including disease areas, intervention techniques, trends in device types, and sample size targets, remains elusive. Therefore, we conducted a comprehensive review of clinical research trends related to wristband wearable devices in research planning and examined their applications in clinical investigations.
As this study identified trends in the adoption of wearable devices during the planning phase of clinical research, including specific disease areas and targeted number of intervention cases, we searched ClinicalTrials.gov-a prominent platform for registering and disseminating clinical research. Since wrist-worn devices represent a large share of the market, we focused on wrist-worn devices and selected the most representative models among them. The main analysis focused on major wearable devices to facilitate data analysis and interpretation, but other wearables were also surveyed for reference. We searched ClinicalTrials.gov with the keywords "ActiGraph,""Apple Watch,""Empatica,""Fitbit,""Garmin," and "wearable devices" to obtain studies published up to 21 August 2022. This initial search yielded 3214 studies. After excluding duplicate National Clinical Trial studies (the overlap was permissible among different device types except for wearable devices), our analysis focused on 2930 studies, including simple, time-series, and type-specific assessments of various variables.
Overall, an increasing number of clinical studies have incorporated wearable devices since 2012. While ActiGraph and Fitbit initially dominated this landscape, the use of other devices has steadily increased, constituting approximately 10% of the total after 2015. Observational studies outnumbered intervention studies, with behavioral and device-based interventions being particularly prevalent. Regarding disease types, cancer and cardiovascular diseases accounted for approximately 20% of the total. Notably, 114 studies adopted multiple devices simultaneously within the context of their clinical investigations.
Our findings revealed that the utilization of wearable devices for data collection and behavioral interventions in various disease areas has been increasing over time since 2012. The increase in the number of studies over the past 3 years has been particularly significant, suggesting that this trend will continue to accelerate in the future. Devices and their evaluation methods that have undergone thorough validation, confirmed their accuracy, and adhered to established legal regulations will likely assume a pivotal role in evaluations, allowing for remote clinical trials. Moreover, behavioral intervention therapy utilizing apps is becoming more extensive, and we expect to see more examples that will lead to their approval as programmed medical devices in the future.
背景/目的:关于可穿戴设备在临床研究中的应用,包括疾病领域、干预技术、设备类型趋势以及样本量目标等方面的信息仍然难以捉摸。因此,我们对与腕带可穿戴设备相关的临床研究趋势进行了全面综述,并研究了它们在临床研究中的应用。
由于本研究确定了在临床研究规划阶段采用可穿戴设备的趋势,包括特定疾病领域和目标干预病例数量,因此我们在 ClinicalTrials.gov 上进行了搜索,该平台是注册和传播临床研究的主要平台。由于腕戴设备占据了市场的很大份额,因此我们专注于腕戴设备,并从中选择了最具代表性的模型。主要分析集中在主要的可穿戴设备上,以方便数据分析和解释,但也调查了其他可穿戴设备作为参考。我们使用“ActiGraph”“Apple Watch”“Empatica”“Fitbit”“Garmin”和“可穿戴设备”等关键词在 ClinicalTrials.gov 上进行了搜索,以获取截至 2022 年 8 月 21 日发布的研究。该初步搜索产生了 3214 项研究。在排除重复的国家临床试验研究(不同设备类型之间的重叠是允许的,除了可穿戴设备之外)之后,我们的分析集中在 2930 项研究上,这些研究包括对各种变量的简单、时间序列和特定类型的评估。
总体而言,自 2012 年以来,越来越多的临床研究纳入了可穿戴设备。虽然 ActiGraph 和 Fitbit 最初主导了这一领域,但其他设备的使用稳步增加,自 2015 年以来约占总数的 10%。观察性研究多于干预性研究,行为和基于设备的干预措施尤为普遍。就疾病类型而言,癌症和心血管疾病约占总数的 20%。值得注意的是,114 项研究在其临床研究中同时采用了多种设备。
我们的研究结果表明,自 2012 年以来,可穿戴设备用于数据收集和各种疾病领域的行为干预的使用一直在增加。过去 3 年来研究数量的增加尤其显著,表明这一趋势在未来将继续加速。经过充分验证、确认准确性并遵守既定法规的设备及其评估方法可能在评估中发挥关键作用,从而实现远程临床试验。此外,利用应用程序进行行为干预疗法的应用越来越广泛,我们预计未来会有更多的例子使其被批准为有编程的医疗器械。